Research and Markets has announced the addition of the “Global Biosimilar Market Outlook 2018” report to their offering.
The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy’s and Merck Serono.
According to “Global Biosimilar Market Outlook 2018”, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. The report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways.
In the report, “Research and Markets” have segmented the biosimilars market into various categories such as EPO (Erythropoietin), HGH (Human Growth Hormone), IFN (Interferon), mAb (Monoclonal Antibody), Insulin and G-CSF (Granulocyte Colony Stimulating Factor). Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expirations of important biologics.
Similarly, major geographies are also discussed. Apart from the most regulated market of Europe, other economies such as US, India, China and Korea have been discussed. The regulatory scenario of all the economies has been presented. India, for example, recently announced its much awaited new and simple regulatory guidelines, Guidelines on Similar Biologics.
At the end, major players based in key economies have been profiled. A brief business overview of these players is given along with approved biosimilar products and the ones in the pipeline. Other than the regular players, the past few years have witnessed the entry of major pharma players into the biosimilars scenario. The strong biosimilar pipelines of these players need to be monitored carefully as they have the potential to change the whole scenario within the near future. Overall, the report will provide a good understanding of the market and the recent trends that are prevailing in it.
Source: Research and Markets